TM-38837

TM-38837
Identifiers
	IUPAC name 1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-(2H-tetrazol-5-ylmethyl)-N-[(1R)-1-[4-(trifluoromethyl)phenyl]ethyl]pyrazole-3-carboxamide;
CAS Number	1034264-77-1;
PubChem CID	66772777;
CompTox Dashboard (EPA)	DTXSID301018782 ;
Chemical and physical data
Formula	C27H20Cl2F3N7O
Molar mass	586.40 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES ClC(C=C1)=C(C=C1)N(N=C1C(=O)N[C@H](C)C(C=CC2C(F)(F)F)=CC=2)C(=C1CC(N=N1)=NN1)C(C=CC1Cl)=CC=1;
	InChI InChI=1S/C27H20Cl2F3N7O/c1-15(16-6-10-18(11-7-16)27(30,31)32)33-26(40)24-20(14-23-34-37-38-35-23)25(17-8-12-19(28)13-9-17)39(36-24)22-5-3-2-4-21(22)29/h2-13,15H,14H2,1H3,(H,33,40)(H,34,35,37,38)/t15-/m1/s1; Key:DANBLBWVACCFGQ-OAHLLOKOSA-N;

TM-38837 is a small molecule inverse agonist/antagonist of the CB₁ cannabinoid receptor, with peripheral selectivity. It is being developed for the treatment of obesity and metabolic disorders by 7TM Pharma.^[1] The company has announced phase I clinical trials.

TM-38837 is among the first of a new generation of cannabinoid receptor antagonist designed to avoid the central nervous system liabilities of the first generation CB₁ receptor antagonists such as rimonabant. The structure of TM-38837 has been erronously referred to in the past as compound 8 in reference ^[2] but is now known from a more recent reference.^[3]

References

^ "7TM Pharma". Archived from the original on July 7, 2011. Retrieved January 18, 2011.
^ Hung MS, Chang CP, Li TC, Yeh TK, Song JS, Lin Y, et al. (September 2010). "Discovery of 1-(2,4-dichlorophenyl)-4-ethyl-5-(5-(2-(4-(trifluoromethyl)phenyl)ethynyl)thiophen-2-yl)-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide as a potential peripheral cannabinoid-1 receptor inverse agonist". ChemMedChem. 5 (9): 1439–1443. doi:10.1002/cmdc.201000246. PMID 20652930. S2CID 34244587.
^ Cooper ME, Nørregaard PK, Andersson G, Linget JM, Högberg T, Little PB, Receveur JM, Elling CE (December 2025). "Efficacy of the Hepatotropic Peripheral CB1R Inverse Agonist TM38837 in Rat Models of Obesity and Metabolic Syndrome". J. Mol. Clin. Med. 8 (1) 36687. doi:10.31083/jmcm36687.

External links

Experimental obesity drug avoids brain effects that troubled predecessors, press release

This cannabinoid related article is a stub. You can help Wikipedia by adding missing information.

[1] "7TM Pharma". Archived from the original on July 7, 2011. Retrieved January 18, 2011.

[2] Hung MS, Chang CP, Li TC, Yeh TK, Song JS, Lin Y, et al. (September 2010). "Discovery of 1-(2,4-dichlorophenyl)-4-ethyl-5-(5-(2-(4-(trifluoromethyl)phenyl)ethynyl)thiophen-2-yl)-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide as a potential peripheral cannabinoid-1 receptor inverse agonist". ChemMedChem. 5 (9): 1439–1443. doi:10.1002/cmdc.201000246. PMID 20652930. S2CID 34244587.

[3] Cooper ME, Nørregaard PK, Andersson G, Linget JM, Högberg T, Little PB, Receveur JM, Elling CE (December 2025). "Efficacy of the Hepatotropic Peripheral CB1R Inverse Agonist TM38837 in Rat Models of Obesity and Metabolic Syndrome". J. Mol. Clin. Med. 8 (1) 36687. doi:10.31083/jmcm36687.

[1]

[2]

[3]

See also

References

External links